Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics


Magenta Therapeutics, Inc. (MGTA)

Today's Latest Price: $8.94 USD

0.11 (1.25%)

Updated Jul 8 4:00pm

Add MGTA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MGTA Daily Price Range
MGTA 52-Week Price Range

MGTA Stock Price Chart Technical Analysis Charts


MGTA Price/Volume Stats

Current price $8.94 52-week high $16.19
Prev. close $8.83 52-week low $5.76
Day low $8.70 Volume 521,035
Day high $9.16 Avg. volume 214,978
50-day MA $9.18 Dividend yield N/A
200-day MA $10.62 Market Cap 352.99M

Magenta Therapeutics, Inc. (MGTA) Company Bio


Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.


MGTA Latest News Stream


Event/TimeNews Detail
Loading, please wait...

MGTA Latest Social Stream


Loading social stream, please wait...

View Full MGTA Social Stream

Latest MGTA News From Around the Web

Below are the latest news stories about Magenta Therapeutics Inc that investors may wish to consider to help them evaluate MGTA as an investment opportunity.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

NEW YORK, NY / ACCESSWIRE / July 6, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA). Such ...

Yahoo | July 6, 2020

Magenta (MGTA) Looks Good: Stock Adds 5.2% in Session

Magenta (MGTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Yahoo | July 6, 2020

Big DraftKings Investor Bought Up an Embattled Biotech Stock

An Atlas Venture affiliate just paid $10 million for more shares of Magenta Therapeutics. Atlas is also the fourth-largest shareholder in sports-betting company DraftKings.

Yahoo | July 5, 2020

Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at a price to the public of $8.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $69.0 million.

Yahoo | June 30, 2020

Magenta Therapeutics prices equity offering at $8

Magenta Therapeutics (MGTA) has priced its public offering of 7.5M common shares at $8.00/share, for expected gross proceeds of $60M.Underwriters' over-allotment is an additional 1,125,000 shares. Closing date is June 29.Previously: Magenta Therapeutics announces $60M equity offering (June 24)...

Seeking Alpha | June 25, 2020

Read More 'MGTA' Stories Here

MGTA Price Returns

1-mo -12.35%
3-mo 26.63%
6-mo -41.34%
1-year -34.55%
3-year N/A
5-year N/A
YTD -41.03%
2019 165.96%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9302 seconds.